Holen Sie sich die Stockscreener-App
1.17
6.40%
-0.08
Handel nachbörslich:
1.17
Rapt Therapeutics Inc Aktie (RAPT) Neueste Nachrichten
Q1 EPS Forecast for RAPT Therapeutics Increased by Analyst - Defense World
Equities Analysts Set Expectations for RAPT FY2026 Earnings - Defense World
RAPT Therapeutics (NASDAQ:RAPT) Given “Buy” Rating at HC Wainwright - Defense World
RAPT Therapeutics: Strategic Licensing and Strong Cash Position Support Buy Rating Despite Financial Loss - TipRanks
RAPT Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Double Feature: RAPT Therapeutics Takes Center Stage at Major Healthcare Investment Forums - StockTitan
Promising Developments and Strategic Trials Boost RAPT Therapeutics’ Buy Rating - TipRanks
RAPT Therapeutics Focuses on RPT904 Development in 2025 - TipRanks
RAPT Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RAPT THERAPEUTICS Earnings Results: $RAPT Reports Quarterly Earnings - Nasdaq
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
RAPT Therapeutics, Inc. SEC 10-K Report - TradingView
Rapt Therapeutics reports Q4 EPS ($1.14), consensus (36c) - TipRanks
Can RAPT's $231M War Chest and New Food Allergy Drug Transform Its Future? - StockTitan
RAPT Therapeutics Inc. (RAPT) reports earnings - Quartz
RAPT Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
RAPT Therapeutics (RAPT) to Release Quarterly Earnings on Thursday - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts - Defense World
Still Cautious Over RAPT Therapeutics’ Fresh Start With RPT904 (NASDAQ:RAPT) - Seeking Alpha
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
SG Americas Securities LLC Purchases 42,636 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
FY2024 Earnings Forecast for RAPT Issued By Leerink Partnrs - Defense World
All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy - Yahoo Finance
RAPT Therapeutics Inc (NASDAQ: RAPT) Up 31.9% From 52-Week Low; YTD Falls -26.58% – Here’s What To Do Now - Marketing Sentinel
A stock that deserves closer examination: RAPT Therapeutics Inc (RAPT) - US Post News
A stock that deserves closer examination: Solidion Technology Inc (STI) - US Post News
Analytical Lens: Exploring RAPT Therapeutics Inc (RAPT)’s Financial Story Through Ratios - The Dwinnex
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Recommendation of “Hold” by Brokerages - Defense World
Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com
SEC Form 424B3 filed by RAPT Therapeutics Inc. - Quantisnow
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull - MSN
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Stake Boosted by Barclays PLC - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Sold by Jane Street Group LLC - Defense World
RAPT Therapeutics Plans Phase 2b Trials for RPT904 - TipRanks
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Purchased by Barclays PLC - Defense World
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
RAPT Therapeutics appoints new board chair By Investing.com - Investing.com Nigeria
Finance Watch: Generation Bio, CytomX Right-Size Operations Ahead Of J.P. Morgan - Citeline News & Insights
RAPT Therapeutics appoints new board chair - Investing.com
RAPT Therapeutics, Inc. Announces Board Changes - Marketscreener.com
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors - The Manila Times
RAPT Therapeutics Announces Leadership Changes and Realignment - TipRanks
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $9.56 Average Target Price from Brokerages - MarketBeat
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Rating of “Hold” from Analysts - Defense World
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - News & Insights
Short Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Grows By 25.5% - MarketBeat
Notable analyst calls this week: FREYR Battery, Apple and ServiceNow among top picks - Seeking Alpha
Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright - Yahoo Finance
RAPT Therapeutics (NASDAQ:RAPT) Upgraded by HC Wainwright to Buy Rating - Defense World
RAPT rockets 180% on licensing deal, $150M private placement (update) - MSN
RAPT Therapeutics Shares Surge After HC Wainwright Upgrade - Marketscreener.com
HC Wainwright & Co. Upgrades RAPT Therapeutics (RAPT) - MSN
RAPT upgraded at H.C. Wainwright on China licensing deal - MSN
RAPT stock upgraded at H.C. Wainwright (RAPT:NASDAQ) - Seeking Alpha
RAPT Therapeutics (NASDAQ:RAPT) Upgraded by HC Wainwright to "Buy" Rating - MarketBeat
RAPT Therapeutics Announces License Agreement and Private Placement - Defense World
RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement - Yahoo Finance
1.39%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):